您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 激素内分泌药物->生长激素
处方药:处方药
包装规格: 15毫克/1.5毫升/支/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
诺和诺德制药公司
生产厂家英文名:
NOVO NORDISK INC
该药品相关信息网址1:
http://www.rxlist.com/norditropin-drug.htm
该药品相关信息网址2:
http://baike.baidu.com/view/775822.html
该药品相关信息网址3:
http://www.norditropin-us.com/
原产地英文商品名:
NORDITROPIN 15MG/1.5ML/PEN/BOX
原产地英文药品名:
SOMATROPIN RECOMBINANT
中文参考商品译名:
诺德欣 15毫克/1.5毫升/支/盒
中文参考药品译名:
基因重组人生长激素
曾用名:
健高灵
原产地国家批准上市年份:
2000/06/20
英文适应病症1:
children with growth failure due to inadequate secretion of endogenous growth hormone
英文适应病症2:
Turner syndrome
临床试验期:
完成
中文适应病症参考翻译1:
儿童因内源性生长激素分泌不足导致的生长障碍
中文适应病症参考翻译2:
特纳综合征
药品信息:

------------------------------------------------------
详细处方信息以本药内容附件PDF文件(2009122200241124.pdf)的“原文Priscribing Information”为准
------------------------------------------------------
部分中文 Norditropin 处方信息(仅供参考)

DRUG DESCRIPTION
Norditropin is a registered trademark of Novo Nordisk Health Care AG for somatropin, a
polypeptide hormone of recombinant DNA origin. The hormone is synthesized by a special strain of E. coli bacteria that has been modified by the addition of a plasmid which carries the gene for human growth hormone. Norditropin contains the identical sequence of 191 amino acids constituting the naturally occurring pituitary human growth hormone with a molecular weight of about 22,000 Daltons.Norditropin cartridges are supplied as sterile solutions for subcutaneous injection in ready-to-administer cartridges or prefilled pens with a volume of 1.5  

INDICATIONS
Pediatric Patients
Norditropin is indicated for the long-term treatment of children with growth failure due to
inadequate secretion of endogenous growth hormone.
Adult Patients
Norditropin cartridges [somatropin (rDNA origin) injection] is indicated for replacement of
endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria.
Adult Onset: Patients who have growth hormone deficiency, either alone or associated with
multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma.
Childhood Onset: Patients who were growth hormone deficient during childhood as a result of
congenital, genetic, acquired, or idiopathic causes.
In general, confirmation of the diagnosis of adult growth hormone deficiency in both groups
usually requires an appropriate growth hormone stimulation test. However, confirmatory growth hormone stimulation testing may not be required in patients with congenital/genetic growth hormone deficiency or multiple pituitary hormone deficiencies due to organic disease.

Stability And Storage
Norditropin® cartridges (somatropin [rDNA origin] injection) 5 mg/1.5 mL, 10 mg/1.5 mL, and 15
mg/1.5 mL:
Non-injected/unused Norditropin cartridges must be stored at 2-8°C/36-46°F (refrigerator). Do
not freeze. Avoid direct light.
Norditropin cartridges retain their biological potency until the date of expiry indicated on the
label.
15 mg/1.5 mL (green) cartridges:
After a Norditropin 15 mg/1.5 mL cartridge has been inserted into the NordiPen 15 injector, it
must be stored in the pen in the refrigerator (2-8°C/36-46°F) and used within 4 weeks. Discard unused portion after 4 weeks.

SIDE EFFECTS
Sudden death in pediatric patients with Prader-Willi syndrome with risk factors including severe
obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection ;Intracranial tumors, in particular meningiomas, in teenagers/young adults treated with radiation to the head as children for a first neoplasm and somatropin ;Glucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes mellitus ;Intracranial hypertension ;Significant diabetic retinopathy;Slipped capital femoral epiphysis in pediatric patients.

[药品名]基因重组人生长激素
[英文名]Recombinant SomatroPin
[别名]健高灵,Humatrpe,Genotropin,Norditropin,DNA—rhGH。
[作用与用途]本品具有与人体生长激素同等的作用,即能促进骨骼、内脏和全身生长,促进蛋白质合成,影响脂肪和矿物质代谢,在人体生长发育中起着关键性作用。皮下注射约80%被吸收,5小时后达高峰血浓度,t1/2约4小时。主要用于内源性脑垂体生长激素分泌不足而引起的生长障碍、躯体矮小的侏儒症、短小病患儿。此外,尚可用于治疗烧伤、骨折、创伤、出血性溃疡、组织坏死、肌肉萎缩症、骨质疏松等疾病。
[用法与用量]本品给药剂量个体差异很大,采用肌内注射或皮下注射,一般用量为每周0.5—0.7单位/kg或每周12单位/m2,分6—7次给药。
[注意事项]偶可引进皮肤过敏、注射部位发红和皮下脂肪萎缩、氨基转移酶升高、呕吐及腹痛等。
1.肿瘤患者、糖尿病患者、颅内进行性损伤者禁用。
2,对脑肿瘤的垂体抹儒病者、心脏或肾脏病者、孕妇和哺乳妇女等慎用。
3.使用前,需对脑垂体功能作详细检查,准确诊断后才能应用。
4.应临用时配制,用注射用水溶解,轻轻摇动,切勿振荡,以免变性。
[贮藏]2℃-8℃保存。有效期为1.5年。
[制剂]注射用基因重组人生长激素:每瓶4单位;12单位。
肾上腺皮质激素及促肾上腺皮质激素
肾上腺皮质分泌有多种激素,在化学构造上都属于甾醇类,为环戊烷多氢菲的衍生物。其构造上的共同点是:在C3上有酮基,C4或C5之间为双键,在C17上有还原性的酮醇基侧链。
肾上腺皮质分泌的激素根据其生理功能可分为三类:
1.糖皮质素类在C11上有氧原子,包括皮质酮、可的松和氢化可的松等。它们对糖的代谢作用强而对钠及钾的作用相对地较弱。由肾上腺皮质束状带细胞所合成和分泌。
2.盐皮质素类在C11上无氧原子,包括11-去氧皮质酮及17-羟基11-去氧皮质酮。它们对于矿物质的代谢特别是促进钠的潴留及钾的排泄的作用很强。醛固酮在C11上虽有氧,但因在体内呈半缩醛式,氧原了被包围在内酯环中,故不呈糖皮质素类作用而呈现较强的盐皮质素类的作用。盐皮质激素都是由肾上腺皮质的球状带分。                                                             3.氮皮质素类包括雄激素(如去氢异雄酮)和雌激素(黄体酮、雌二醉)。性激素不仅由性腺分泌,肾上腺皮质的网状带亦为其制造场所。但雌激素主要由卵巢分泌,皮质分泌的量极少;而雄激素则皮质分泌的量较大(特别是女性体内的雄激素几全部由此处产生)。  

 

 

------------------------------------------------------
详细处方信息以本药内容附件PDF文件(2009122200241124.pdf)的“原文Priscribing Information”为准
------------------------------------------------------

更新日期: 2011-9-5
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com